Abstract:Rationale: Vascular calcification (VC) is a marker of the severity of atherosclerotic disease. Hormones play important roles in regulating calcification; estrogen and parathyroid hormones exert opposing effects, the former alleviating VC and the latter exacerbating it. To date no treatment strategies have been developed to regulate clinical VC. Objective: The objective of this study was to investigate the effect of growth hormone–releasing hormone (GHRH) and its agonist (GHRH-A) on the blocking of VC in a mouse model. Methods and Results: Young adult osteoprotegerin-deficient mice were given daily subcutaneous injections of GHRH-A (MR409) for 4 weeks. Significant reductions in calcification of the aortas of MR409-treated mice were paralleled by markedly lower alkaline phosphatase activity and a dramatic reduction in the expression of transcription factors, including the osteogenic marker gene Runx2 and its downstream factors, osteonectin and osteocalcin. The mechanism of action of GHRH-A was dissected in smooth muscle cells isolated from human and mouse aortas. Calcification of smooth muscle cells induced by osteogenic medium was inhibited in the presence of GHRH or MR409, as evidenced by reduced alkaline phosphatase activity and Runx2 expression. Inhibition of calcification by MR409 was partially reversed by MIA602, a GHRH antagonist, or a GHRH receptor–selective small interfering RNA. Treatment with MR409 induced elevated cytosolic cAMP and its target, protein kinase A which in turn blocked nicotinamide adenine dinucleotide phosphate oxidase activity and reduced production of reactive oxygen species, thus blocking the phosphorylation of nuclear factor κB (p65), a key intermediate in the ligand of receptor activator for nuclear factor-κ B-Runx2/alkaline phosphatase osteogenesis program. A protein kinase A–selective small interfering RNA or the chemical inhibitor H89 abolished these beneficial effects of MR409. Conclusions: GHRH-A controls osteogenesis in smooth muscle cells by targeting cross talk between protein kinase A and nuclear factor κB (p65) and through the suppression of reactive oxygen species production that induces the Runx2 gene and alkaline phosphatase. Inflammation-mediated osteogenesis is thereby blocked. GHRH-A may represent a new pharmacological strategy to regulate VC.

Blockade of Angiotensin II Type 2 Receptor by PD123319 Inhibits Osteogenic Differentiation of Human Mesenchymal Stem Cells Via Inhibition of Extracellular Signal-Regulated Kinase Signaling

Local Renin Angiotensin Expression Regulates Human Mesenchymal Stem Cell Differentiation to Adipocytes.

Zoledronate Attenuates Angiogenic Effects Of Angiotensin Ii-Stimulated Endothelial Progenitor Cells Via Rhoa And Mapk Signaling

Deletion of Angiotensin II Type 2 Receptor Accelerates Adipogenesis in Murine Mesenchymal Stem Cells Via Wnt10b/beta-catenin Signaling

Angiotensin II/Angiotensin II Receptor Blockade Affects Osteoporosis Via the AT1/AT2-Mediated Camp-Dependent PKA Pathway

Abstract 3145: Inactivating the Adenosine 2A Receptor Reduces Vascular Calcification Through Modulating Osteogenic Differentiation of Vascular Cells

Abstract 3719: Deletion of Angiotensin II Type 2 Receptor Accelerates Adipogenesis in Murine Mesenchymal Stem Cells with Wnt 10B/beta-Catenin Signaling: Potential Link to Obesity and Metabolic Syndrome

Activation of the AT1R/HIF-1 Α /ACE Axis Mediates Angiotensin II-induced VEGF Synthesis in Mesenchymal Stem Cells.

The Effect of MMP-2 Inhibitor 1 on Osteogenesis and Angiogenesis During Bone Regeneration.

[Effects of Angiotensin II on Extracellular Signal-Regulated Protein Kinases Signaling Pathway in Cultured Vascular Smooth Muscle Cells from Wistar-Kyoto Rats and Spontaneously Hypertensive Rats].

Angiotensin-(1-7) Inhibits Vascular Calcification in Rats

Glucagon-Like Peptide Receptor Agonist Inhibits Angiotensin II-Induced Proliferation and Migration in Vascular Smooth Muscle Cells and Ameliorates Phosphate-Induced Vascular Smooth Muscle Cells Calcification

Apelin Attenuates the Osteoblastic Differentiation of Vascular Smooth Muscle Cells

Abstract 5254: The Role of Caveolae on the Inhibition of Coronary Arterial BK Channels by Angiotensin II in Control and Diabetic Rats

ERK1/2 inhibition reduces vascular calcification by activating miR-126-3p-DKK1/LRP6 pathway

Angiotensin Ii Promotes Smooth Muscle Cell Proliferation and Migration Through Release of Heparin-Binding Epidermal Growth Factor and Activation of Egf-Receptor Pathway

Platelet-derived Growth Factor Receptor-Β in Myocyte Was Upregulated by Angiotensin II

[Effect of Ang II on PDGF Receptor Expression in Vascular Smooth Muscle Cell].

Regulation of Vascular Calcification by Growth Hormone-Releasing Hormone and Its Agonists

Role of Angiotensin Ⅱ in the Regulation of Platelet-Derived Growth Factor Receptor Β Subunit of Vascular Smooth Muscle

Losartan Inhibited Expression of Matrix Metalloproteinases in Rat Atherosclerotic Lesions and Angiotensin II-stimulated Macrophages.